The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

Expert Opinion on Biological Therapy

Volumn 11, Issue 5, 2011, Pages 551-557

  Musto, Pellegrino ^a   D'Auria, Fiorella ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Anti CD20 monoclonal antibodies; CD20 antigen; CD20 modulation; chronic lymphocytic leukemia; non Hodgkin's lymphoma; Richter's syndrome; rituximab

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; RITUXIMAB;

APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; DRUG ACTIVITY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LOW DRUG DOSE; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE; NONHODGKIN LYMPHOMA; PHAGOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOPROLIFERATIVE DISORDERS;

EID: 79953875843     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.567262     Document Type: Review

References (52)

1. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85 (Pubitemid 10018582)
2. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95 (Pubitemid 27392702)
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33 (Pubitemid 28363048)
4. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37 (Pubitemid 47332625)
5. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-17
6. Ernst JA, Li H, Kim HS, et al. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005;44:15150-8 (Pubitemid 41681449)
7. Binder M, Otto F, Mertelsmann R, et al. The epitope recognized by rituximab. Blood 2006;108:1975-8 (Pubitemid 44395009)
8. Riley JK, Silwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000; 27: 17-24 (Pubitemid 32164592)
9. Deans JP, Kalt L, Ledbetter JA, et al. Association of 75/80-kappaDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of the cytoplasmic regions of CD20. J Biol Chem 1995;270:22632-8
10. Popoff IJ, Savage JA, Blake J, et al. The association between CD20 and Src-family tyrosine kinases requires an additional factor. Mol Immunol 1998;35:207-14 (Pubitemid 28374928)
11. Manshouri T, Do K, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507-13 (Pubitemid 36857605)
12. Alatrash G, Albitar M, O'Brien S, et al. Circulating CD52 and CD20 levels at the end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 2009;148:386-93
13. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transpl 2006;6:859-66 (Pubitemid 44356635)
14. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implication for therapy. Oncologist 2008;13:954-66
15. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8 (Pubitemid 30412866)
16. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7 (Pubitemid 36900094)
17. Hammadi M, Pers JO, Berthou C, et al. A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency. Onco Targets Ther 2010;3:99-109
18. Davis AT, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-15 (Pubitemid 29131971)
19. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71 (Pubitemid 43939148)
20. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102:3514-20 (Pubitemid 37419939)
21. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201
22. Tomita A, Hiraga J, Kiyoi H, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007;86:49-57 (Pubitemid 47204490)
23. Sugimoto T, Tomita A, Hiraga J, et al. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 2009;390:48-53
24. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561-70 (Pubitemid 351413941)
25. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-8 (Pubitemid 38263720)
26. Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600-9 (Pubitemid 43201712)
27. Schmitz K, Brugger W, Weiss B, et al. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999;106:571-2 (Pubitemid 29450692)
28. Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, et al. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol 2003;82:585-8 (Pubitemid 37220678)
29. Haidar JH, Shamseddine A, Salem Z, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003;70:330-2 (Pubitemid 36560534)
30. Massengale WT, McBurney E, Gurtler J. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. J Am Acad Dermatol 2002;46:441-3 (Pubitemid 34225414)
31. Clarke LE, Bayerl MG, Ehmann WC, Helm KF. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. J Cutan Pathol 2003;30:459-62 (Pubitemid 36920927)
32. Rawal YB, Nuovo GJ, Frambach GE, et al. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 2005;32:616-21 (Pubitemid 41415090)
33. Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002;119:412-16 (Pubitemid 35365492)
34. Ferreri AJ, Dognini GP, Verona C, et al. Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. Haematologica 2007;92:e1-2
35. Chu PG, Chen YY, Molina A, et al. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 2002;43:2335-41 (Pubitemid 35386157)
36. Goteri G, Olivieri A, Ranaldi R, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol 2006;19:421-31 (Pubitemid 44181964)
37. Seliem RM, Freeman JK, Steingart RH, Hasserjian RP. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol 2006;14:18-23
38. Maeshima AM, Taniguchi H, Nomoto J, et al. Histological and immunophenotypic changes in 59 cases ofB-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci 2009;100:54-61
39. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93
40. Molica S. A systematic review on Richter syndrome: what is the published evidence? Leuk Lymphoma 2010;51:415-21
41. D'Auria F, Guariglia R, Villani O, et al. Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia. Clin Ther 2010;32:1911-16
42. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435-43 (Pubitemid 44715114)
43. Aue G, Lindorfer MA, Beum PV, et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010;95:329-32
44. Van Meerten T, Rozemyller H, Hol S, et al. Hu-Mab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab mediated lysis. Haematologica 2010;95:2063-71
45. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010;28:3525-30
46. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 moAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009;10:588-96
47. van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010;47:199-210
48. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51:983-94
49. Illidge T, Chan C How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? Leuk Lymphoma 2008;49:1263-73 (Pubitemid 352022536)
50. Sonet A, Bosly A. Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2009;9:719-26
51. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74
52. Cartron G, Dacheux L, Salles G. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8 (Pubitemid 34525533)